CAMBRIDGE, Mass.--(BUSINESS WIRE)--Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today presented new data on its novel gene-silencing oligonucleotide (GSO) technology at the 12th annual EuroTIDES conference being held in Berlin, Germany November 15-16, 2011. The preclinical data demonstrated that GSOs exert target-specific gene-silencing activity following systemic delivery and, due to their novel structure, minimize the sequence-dependent immune stimulation that is associated with other approaches to gene-silencing.
